Home » Newsletters » BioWorld Science

BioWorld Science

May 30, 2001

View Archived Issues

Licensing opportunity from NIH: human nuclear receptor corepressor gene

Antibodies that selectively detect human nestin protein available from NIH

Licensing opportunity from NIH: bispecific fusion proteins for HIV infection

Yamanouchi identifies ethenesulfonamide ETA antagonist with good selectivity and oral activity

Synthetic IFN-gamma-derived peptide delays rejection of vascularized skin allografts

New combination treatment for malaria launched in Europe

Novartis launches Foradil Aerolizer in the U.S.

European group develops new molecular modeling tools for H3 antagonists

Locally active estrogens useful for menopausal vaginal dyspareunia

Telik begins phase II trial of TLK-286 for treatment of ovarian cancer

Oxxon Pharmaccines begins melanoma pharmaccine trials

ISAtx-247 highlighted at Transplant 2001 as having potential advantages over ciclosporin

Company Profile: Galileo Laboratories

Prescient NeuroPharma establishes collaboration with CNRS

Recombinant AAT closer to obtaining orphan drug designation in E.U.

Favorable phase I data presented for Bay-43-9006 at ASCO

Solid dosage form of antibody for UC to be developed by KS Biomedix and MedPharm

Combination therapy containing IMC-C225 beneficial in cancer patients with limited options

Takeda's Ixense approved in Europe for ED

Company Profile: Consensus

MCH antagonists and their utility described by Takeda

Potent new PDE5 inhibitors designed by Pfizer group

Improvement in glucose tolerance and insulin secretion produced by Shionogi compounds

Quinazolinones and related compounds and use as local anesthetics

New CCR5 antagonists designed at Takeda as agents for HIV

New antifungal/antibacterial enediyne compounds

Welfide describes new research in the area of cytokine modulation

Inhibitors of 5-HT reuptake and potential therapeutic applications presented by ADIR

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...